NCT00798837

Intraprostatic MAXimal Simultaneous Boost

A Dose-escalation Study Using a Maximal Simultaneous Intraprostatic Boost With RapidArc Intensity Modulated Radiotherapy in Intermediate Risk Prostate Cancer

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: British Columbia Cancer Agency · Academic / Other
• Sex: Male
• Age: —
• Healthy volunteers: Not accepted

Summary

This trial uses a type of radiotherapy called intensity modulated radiotherapy (IMRT), which is able to deliver the radiation to the prostate while delivering less dose to the surrounding normal organs compared with standard 3D conformal radiotherapy presently used at the BCCA. This trial will use RapidArc IMRT, which is a new way of delivering IMRT, where the radiation dose is delivered in a single rotation of the radiotherapy machine around the patient. This new method of delivering IMRT has been shown to be at least as good as conventional IMRT at delivering the dose, and takes less time to do so. The aim of this study is to deliver a higher radiation dose to the prostate gland than the standard treatment while not increasing dose to the normal organs. In this way, it is hoped that the likelihood of the cancer coming back will be reduced without causing an increase in side-effects.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
RADIATION	Intraprostatic maximal simultaneous boost	Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery. Doses of radiotherapy are as follows: * The prescription dose will be 73.7 Gy in 28 fractions * A simultaneous intraprostatic boost will be given to as much of the CTV as possible without contravening OAR dose constraints.

Timeline

• Start date: 2008-12-01
• Primary completion: 2016-10-01
• Completion: 2016-10-01
• First posted: 2008-11-26
• Last updated: 2018-07-11

Locations

1 site across 1 country: Canada